Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.44 |
| ▸ | CSF1R | P07333 | 10/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323140 | 0.92 | CHEK1 (0.36) | KITDDR1CSF1RCHEK1PIM1 | |
| SCHEMBL15907282 | 0.87 | CHEK1 (0.38) | KITDDR1CSF1RCHEK1PIM1 | |
| SCHEMBL15907285 | 0.84 | GPR6 (0.36) | DDR1CHEK1PIM1MAPK8CLK4 | |
| SCHEMBL15907289 | 0.79 | CSF1R (0.43) | KITDDR1CSF1RABL1DDR2 | |
| SCHEMBL15907284 | 0.79 | MAP3K5 (0.32) | — | |
| SCHEMBL15907288 | 0.75 | SMO (0.41) | KITDDR1ABL1 | |
| SCHEMBL15907192 | 0.74 | KIT (0.44) | KITDDR1CSF1R | |
| SCHEMBL15907292 | 0.73 | GPR6 (0.38) | — | |
| SCHEMBL15907240 | 0.72 | NPC1 (0.42) | KITDDR1CSF1RABL1 | |
| SCHEMBL18323617 | 0.71 | MAP3K5 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KIT 577/4885DDR1 2472/4885CSF1R 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.